Bone-related sulfatase-like protein and process for its production

Abstract: A bone-related protein named OSF-8 which is obtained from bone tissue of a mammal including mouse or human, and a process for its production. This protein is a novel naturally occurring mammal protein which belongs to a group of sulfatases. OSF-8 degrades the sulfate groups of the sugar chains of proteoglycan, which makes up the cartilage matrix, during the replacement of cartilage into bone tissue at the stage of osteogenesis. OSF-8 can be used as an agent for treating bone metabolic diseases, and its high organ specificity for bones enables its use as a diagnostic reagent for bone metabolic diseases.

Description: The present invention provides a novel bone-related protein. This invention relates to a novel protein having the abilities to form and maintain bones as well as cartilages (a novel sulfatase, OSF-8); a method for measuring its activity; a method for detecting an inhibitor or enhancer of its activity; DNA coding for the OSF-8 and a process for the production of that protein by a genetic engineering technique using the DNA; and applications of specific antibodies, comprising the purified protein, the genetically engineered protein, or a partial peptide thereof, to immunoassay for diagnosis of metabolic bone diseases. Bone metabolic diseases include osteoporosis, Paget's disease, osteomalacia, hyperostosis, and osteopetrosis. Osteoporosis, in particular, has a high incidence enough to affect about more than a half of postmenopausal women and elderly people, and effective methods for its diagnosis and treatment have been strongly desired. Bone metabolic diseases involve some disorder of bone metabolism at the cellular level in bone tissue. The discovery, isolation and identification of factors associated specifically with bone metabolism are very effective for elucidating this disorder. A cell line of an osteoblast, which plays a major role in osteogenesis, was used to identify a proteinaceous factor produced specifically by this cell line. Therefore, the present invention provides a novel protein named OSF-8 which is substantially bone-specific, and which has a high homology with various known sulfatases in terms of amino acid sequence. OSF-8 can also be produced from the DNA sequence described in the present specification by an ordinary genetic engineering technique known in the art. Furthermore, the OSF-8 or its fragment can be produced from the amino acid sequence described in the specification by a chemical peptide synthesis method. Moreover, that fragment of the DNA sequence of the OSF-8 described in the present invention which has a high specificity particularly for other sulfatases can be synthesized with a length of 15 to 50 bases by an ordinary chemical oligonucleotide synthesis method. That fragmentary sequence can be used as a DNA probe for finding and identifying bone-derived cells. This identification of bone-derived cells is useful particularly for grasping the origin of metastatic or recurrent carcinoma, thus leading to an appropriate therapy for recurrent cancer. Of the partial peptides of the OSF-8, the peptide in the epitope portion that can be recognized by antibodies is usable for preparing a monoclonal antibody specific for OSF-8. The resulting monoclonal antibody is of marked value for identifying bone-derived cells by an immunological cell tissue staining method. The following is known about the relationship between bone metabolism and the enzymes in a group of sulfatases where the OSF-8 belongs. Histological observations have shown that cartilages are first formed during osteogenesis of long bones and in the fractured bone repairing process. In the process of calcification of the cartilages, angiogenesis is observed and migrated cells such as osteoblasts and osteoclasts can change the cartilages into bone tissue, although details of the mechanisms at the protein level are unknown. In addition to the presence of calcium phosphate deposition in bone, a marked difference in the constitution of the matrix protein is known between the bone and the cartilage. More than 50% of the dry weight of the cartilage is large proteoglycan, and the collagen involved is type II. Whereas more than 90% of the bone is type I collagen; large proteoglycan in the cartilage disappears at cartilage ossification, and only small proteoglycan and non-collagenous proteins are present. Thus, marked replacement of the matrix is inevitable during the process of cartilage ossification. Migrated cells, most likely, osteoblasts and osteoclasts, may play a central role in the digestion of the cartilage as well as the construction of the osteoid. These osteoblasts have been shown to differentiate from mesenchymal cells, suggesting that they may migrate, attendant on angiogenesis, into the tissue prior to the ossification of the mesochondrium. The absorption of the cartilage requires not only the presence of collagenase which digests type II collagen accounting for about 50% of the cartilage matrix proteins, but also the digestion of sugar chains having sulfate groups present widely in the cartilage (e.g. chondroitin sulfate, keratan sulfate). To date, however, there have been no reports of sulfuric ester hydrolases (sulfatases) inherent in cartilage and bone tissue. On the other hand, the involvement of estrogen in bone metabolism is well known. Osteoporosis occurs in many postmenopausal women, and the administration of estrogen to these patients can inhibit the loss of bone mineral volume. However, the concrete mechanism of action of estrogen in bone tissue is unclear. Estrogen is biosynthesized in breast cancer cells that are highly sensitive to it. Aromatase which takes part in the conversion of androgen into estrogen, and sulfatase which synthesizes estrogen from estrone sulfate are attracting attention as estrogen synthesizing enzymes. In recent years, osteoblasts have been reported to have aromatase activity. It is highly conceivable that the sulfatase described in the present specification may contribute to estrogen synthesis in osteoblasts. During the period of normal gonadal function, such estrogen synthesis in osteoblasts is physiologically unimportant. After menopause, hormone synthesis in peripheral tissues such as osteoblasts may become important, because a sufficient supply of estrogen is not obtained from the gonads. Such a difference in the ability to synthesize estrogen in osteoblasts may explain the fact that not all postmenopausal women show a sharp decrease in bone mineral volume. Thus, the activation of this estrogen synthesis in osteoblasts may prevent postmenopausal osteoporosis. Furthermore, the postmenopausal assay of sulfatase activity against estrone sulfate in osteoblasts may detect a high risk group for osteoporosis at an early stage. However, such sulfatase has not been reported with osteoblasts. Therefore, the object of the present invention is to find a new type of protein with sulfatase activity which is expressed specifically in osteoblasts. Such a protein degrades the sulfate groups of the sugar chains of proteoglycan, which makes up the cartilage matrix, during the replacement of cartilage into bone tissue at the stage of osteogenesis. Said protein is also expected to increase local production of estrogen, particularly, in matured bone tissue, when gonadal function has declined. cDNA of mouse OSF-8 (mOSF-8) was isolated from mouse osteoblastic cell line MC3T3-E1 cDNA library constructed by a combination of PCR (polymerase chain reaction) and the subtraction method, and by the differential screening method. Search through the currently available DNA and amino acid sequence data bases showed the cDNA sequence described in the present invention to be novel. The OSF-8 encoding DNAs of other animals can be obtained from cDNA libraries or genomic libraries constructed from their bones, cultured osteoblasts and other body tissues, by recombinant gene technology using the cDNA or its DNA fragment as a probe. OSF-8, moreover, is a sulfatase molecule which has homology with known representative sulfatase molecules, but which belongs to a new subclass different from those so far reported. That is, the protein indicated in the present specification is an osteoblast-specific sulfatase indispensable for normal osteogenesis. Many diseases involving sulfatase deficiency or mutation are widely known to induce the deformation or functional deterioration of the tissue, because the sulfate group-bearing sugar chains in the tissue cannot be digested, thereby causing accumulation of the undigested matter in the cells. It can be easily speculated that the deficiency and functional disorder of this protein may be one of the causes of congenital diseases such as osteogenesis imperfecta. These congenital diseases can be diagnosed by observing the abnormality of the DNA sequence of this protein. The function of osteoblasts can also be known by measuring the activity or concentration of this protein that has been liberated into body fluids. These facts show that the activity and concentration of this protein can be used as markers of bone metabolism. The addition of this protein to cartilage or the bone matrix may also promote osteogenesis. Many bone and cartilage matrix proteins are known to participate in osteogenesis. Of them, growth factors such as TGF-β are considered to be bound to the proteoglycan of the matrices and accumulated there. The addition of sulfatase could promote the release of these growth factors from the matrices. In states involving the excessive resorption of cartilage, such as rheumatoid arthritis or osteoarthritis, the inhibitor of this protein could be an effective therapeutic agent. Generally, the OSF-8 can be directly extracted from bone tissue or cartilage tissue of a human, bovine, murine or other source by a known biochemical technique. The DNA coding for the OSF-8 can be obtained by constructing a cDNA library or a genomic library from mRNA extracted from vertebrate bone tissue, and using a probe comprising a labeled fragment of the mouse DNA sequence disclosed in the present specification. A full length cDNA clone can be obtained by a combination of the above-described and other standard techniques on molecular biology. The present invention further provides polypeptides comprising analogues of OSF-8, i.e. mutants and fused proteins. This invention also provides a process for producing the OSF-8 by recombinant DNA technology. According to the present application the term "hybridization under stringent conditions means hybridization conditions with a salt concentration of 6xSSC (NaCl-citrate puffer) at 62-68°C. Brief Explanation of Figures Figure 1 shows a restriction enzyme map of cDNA coding for mouse OSF-8. The bold letters indicate the region coding for the amino acid of OSF-8. There are no KpnI, PstI, SacI, SalI, SmaI, SphI and XbaI sites. Table 1 shows an alignment of the amino acid sequences of mouse OSF-8 and other salfatase molecules. Common amino acid residues are shown in the form of a consensus. Table 2 shows a continuation of the alignment of the amino acid sequences of mouse OSF-8 and other sulfatase molecules shown in Table 1. Common amino acid residues are shown in the form of a consensus. Table 3 shows a continuation of the alignment of the amino acid sequences of mouse OSF-8 and other sulfatase molecules shown in Table 2. Common amino acid residues are shown in the form of a consensus. It is mentioned that the contents of the Japanese priority applications No. 230030/92 and 324034/92 are a part of the present application. Examples The present invention will be described in more detail by reference to the following Examples: Example 1 Construction of cDNA library by subtraction and PCR The construction of a cDNA library specific for the osteoblastic cell line MC3T3-E1 will be hereinafter described. This cDNA library is constructed by a combination of the subtraction method and the PCR with the gene expressed in mouse liver tissue being subtracted. Each cDNA clone has gene fragments with an average length of about 300 bases, and is characterized in that the gene with a low content has been amplified. Unless otherwise specified, all general recombinant DNA protocols complied with Sambrook et al., "Molecular Cloning Manual" (1989), Cold Spring Harbor Laboratory, Cold Spring Harbor, U.S.A. Total RNAs were extracted from 8x10 7 MC3T3-E1 cells and about 1 g of mouse liver tissue by the guanidine method. Poly A + RNAs were purified from the total RNAs by means of the commercially available product "Oligo dT Latex mRNA Purification Kit" (Takara Shuzo). cDNAs were synthesized by a cDNA synthesis kit (Amersham) using 1 µg of each poly A + RNA as a template. However, a random primer was used, instead of an oligo dT primer, in an amount of 1.5 times its ordinary amount used, whereby the cDNA chain elongation was restricted to an average length of about 300 bases. After the cDNAs were made double-stranded and blunt-ended by use of the above kit, they were joined with T4 DNA ligase (Takara Shuzo) to the following two DNA linkers, i.e. ATOS-1/2 (Sequence ID Nos. 2 and 3 of the Sequence Table) for the MC3T3-E1 cDNA, and ATOS-4/5 (Sequence ID Nos. 4 and 5 of the Sequence Table) for the liver cDNA: Then, each reaction product was subjected to DNA amplification by the PCR (polymerase chain reaction) method using ATOS-1 and ATOS-4, respectively, as primers. The amplified DNA concentration was determined with the DNA assay kit "DNA Dipstick" (Invitrogen). The subtraction method was performed using photobiotin (Pirce). Photobiotin (20 ng) was added to 20 µg of the PCR-amplified liver cDNA, and light from a sunlamp 10 cm apart was projected onto the liver cDNA for 10 minutes to label it with biotin. To 3.0 µg of the labeled liver cDNA was added 0.3 µg of unlabeled MC3T3-E1 cDNA for hybridization. Then, streptavidin (Takara Shuzo) was reacted, and the reaction mixture was extracted with phenol to remove cDNA common to the liver cDNA from the MC3T3-E1 cDNA. The subtraction method was repeated to remove as much of the common cDNA as possible from the MC3T3-E1 cDNA. DNA was amplified by PCR using the aforementioned ATOS-1, and the DNA concentration was measured. This cDNA (10 ng) was digested with the restriction enzyme EcoRI, and then ligated with T4 ligase to 1 µg of the phage vector lambda gt10 (lambda gt10/EcoRI cloning kit, Stratagene) which was digested with EcoRI and dephosphorylated at its ends. The resulting recombinant DNA was packaged into lambda phage particles by use of the in vitro packaging kit "Gigapack-gold" (Stratagene). The recombinant phages were infected into E. coli C600 (preserved as HT003 at Japanese Cancer Research Resources Bank, National Institute of Health of Japan), and the organisms were applied to an agar medium along with a soft agar medium to form phage plaques. The efficiency of infection was determined to be 3x10 6 phage plaques/µg vector DNA. The resulting cDNA library was subjected to differential screening to select clones with a high specificity for MC3T3-E1. Specifically, 2.25x10 4 phages were applied to total 10 plates, and the resulting plaques on each plate were transferred to two nylon membrane filters (total 20 filters). These series of plaques were subjected to plaque hybridization using as the probe radiolabeled MC3T3-E1 cDNA for one of the series, and radiolabeled liver cDNA for the other series. In 273 clones, expression was observed with the MC3T3-E1 cDNA probe, but not with the liver cDNA probe. These clones were used as a mini-library in subsequent experiments. Example 2 Isolation of mouse OSF-8 clone A description will be made of methods to identify a cDNA fragment of OSF-8 as an MC3T3-E1 specific clone from the mini-library constructed in Example 1, and to clone full length cDNA from the cDNA library of MC3T3-E1 with the use of this fragment. The total RNAs from MC3T3-E1 and liver prepared in Example 1 were spotted in an amount of 1 µg each onto nylon membrane filters. 273 of the filters were prepared, and used for hybridization to be described later on. Separately, the DNA of the inserts of the 273 phage clones prepared in Example 1 was amplified by PCR. This DNA was agarose gel electrophoresed, and main bands were cut out, purified, and radiolabeled for use as a probe. A clone showing expression with MC3T3-E1 cDNA but no expression with liver cDNA upon autoradiography was recloned into a plasmid vector. Specifically, the DNA of the inserts amplified by PCR and then purified was digested with the restriction enzyme EcoRI, and recloned into the EcoRI site of the plasmid vector pUC118 (Takara Shuzo). The DNA sequence of the resulting clone was determined with commercially available "DNA Sequence Kit" (Takara Shuzo) using a universal primer. Search through DNA and protein data bases showed that DNA sequence to constitute a clone homologous with the existing sulfatase. This clone was designated as pMCLS63, and used for subsequent cloning of the full length cDNA. For cloning of the full length cDNA, blund-ended double-stranded cDNA was synthesized with the cDNA synthesis kit "cDNA Synthesis System Plus" (Amersham) using 5 µg of the poly A + RNA of MC3T3-E1 purified in Example 1. The resulting cDNA was ligated to EcoRI/NotI adaptor (Takara Shuzo) using T4 ligase, and the product was agarose gel electrophoresed to purify a fragment more than about 700 base pair long. This fragment was joined to the EcoRI site of lambda gt10 phage vector (Stratagene), and packaged into phage particles in the same way as in Example 1. The packages were infected into E. coli as in Example 1, and the efficiency of infection was determined to be 1.5x10 7 phage plaques/µg vector DNA. The aforementioned pMCLS63 was radiolabeled for use as a probe, and 1.0x10 6 phage clones of the cDNA library were screened by plaque hybridization. Eight positive hybridization signals were obtained, whereafter the NotI fragment of the phage clone with the longest insert was recloned into the NotI site of the plasmid vector pGEM11Zf(+) (Stratagene). The resulting clone was designated as pKOT162. Example 3 DNA sequence of mouse OSF-8 Deletion mutants of the pKOT162 and a subclone containing its cDNA fragment were prepared with "the Deletion Kit for Kilo Sequence" (Takara Shuzo) by cutting at intervals of 300 base pairs in each opposite direction. The DNA sequence of each deletion mutant was determined with the automatic DNA sequencer 373A (Applied Biosystems, U.S.A.). The entire DNA sequence of the cDNA, and an amino acid sequence translated from this DNA sequence are shown as Sequence ID No. 1 of the Sequence Table. The protein encoded by this cDNA was designated as OSF-8. No. 1 of the amino acid residue corresponds to the N-terminus of the predicted OSF-8 precursor protein. The restriction enzyme map of that cDNA is shown in Fig. 1, and the homology in the amino acid sequence between the mouse OSF-8 and other sulfatases is shown in Tables 1 to 3. Example 4 Tissue specific expression of mouse OSF-8 RNA dot blotting was performed to investigate the tissue specific expression of mouse OSF-8. The total RNAs of the thymus, spleen, brain, kidney, liver, lung, test is and heart of mice (purchased from Nippon Clea) were prepared by the guanidine method. Calvarial osteoblast-rich cells were obtained from a culture of newborn mice calvaria. Total RNA was extracted from these cells in the same way as described above. One µg of the total RNA each from the above-mentioned tissues, cultured calvarial cells, and MC3T3-E1 was dotted onto nylon membrane filters (Biodyne, PALL), fixed by heating, and used for hybridization. Separately, the pKOT162 was digested with NotI, and purified by agarose gel electrophoresis. Then, the isolate was radiolabeled and used as a probe. Autoradiography indicated high expression for the cultured calvarial cells and MC3T3-E1. OSF-8 provided by the present invention can be used as an agent for treating bone metabolic diseases, and because of its high organ specificity for bones, it can also be used as a diagnostic reagent for bone metabolic diseases. SEQUENCE LISTING (1) GENERAL INFORMATION: (i) APPLICANT: (A) NAME: Hoechst Japan Limited (B) STREET: New Hoechst Building 10-16, Akasaka 8-chome (C) CITY: Minato-Ku, Tokyo (E) COUNTRY: 107 Japan (F) POSTAL CODE (ZIP): - (G) TELEPHONE: (03) 3479-5137 (H) TELEFAX: (03) 3479-7859 (ii) TITLE OF INVENTION: BONE-RELATED SULFATASE-LIKE PROTEIN AND PROCESS FOR ITS PRODUCTION (iii) NUMBER OF SEQUENCES: 5 (iv) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFTWARE: PatentIn Release #1.0, Version #1.25 (EPO) (2) INFORMATION FOR SEQ ID NO: 1: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2373 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (vi) ORIGINAL SOURCE: (A) ORGANISM: Mus musculus (B) STRAIN: osteoblastic cell line MC3T3E1 (ix) FEATURE : (A) NAME/KEY: intron (B) LOCATION: 1..149 (ix) FEATURE : (A) NAME/KEY: CDS (B) LOCATION: 150..1817 (ix) FEATURE : (A) NAME/KEY: intron (B) LOCATION: 1818..2373 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1: (2) INFORMATION FOR SEQ ID NO: 2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (ix) FEATURE: (A) NAME/KEY: intron (B) LOCATION: 1..21 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2: (2) INFORMATION FOR SEQ ID NO: 3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 25 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (ix) FEATURE: (A) NAME/KEY: intron (B) LOCATION: 1..25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3: (2) INFORMATION FOR SEQ ID NO: 4: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (ix) FEATURE: (A) NAME/KEY: intron (B) LOCATION: 1..21 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4: (2) INFORMATION FOR SEQ ID NO: 5: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 25 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (ix) FEATURE: (A) NAME/KEY: intron (B) LOCATION: 1..25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

Claims: A protein comprising mouse OSF-8 having the amino acid sequence from residue 19 to residue 556 of Sequence ID No. 1 of the Sequence Listing, or an analogue of the mouse OSF-8. A protein comprising the OSF-8 precursor protein having an amino acid sequence from residue 1 to residue 556, including a signal peptide from the 1st to the 18th residue of Sequence ID No. 1 of the Sequence Listing; or an analogue of the precursor protein. DNA or RNA coding for the protein of Claim 1 or 2. DNA or RNA hybridizing under stringent conditions with DNA or RNA according to claim 3. A process for the production of a recombinant mammalian OSF-8 protein according to claim 1, or an analogue thereof, or a fragment thereof, comprising the steps of: (a) obtaining a population of host cells containing a heterologous DNA composed of the following DNA sequences: (i) a sequence which can function in the cells to control transcription and translation, and (ii) a DNA sequence according to claims 3-4 joined downstream of said controlling sequence to code for said recombinant protein, and (b) culturing said population of cells under conditions which permit the production of said recombinant protein. The process of Claim 5 wherein the controlling sequence further contains a DNA coding for a signal peptide for secreting said recombinant protein extracellularly such that said DNA is positioned immediately upstream of said DNA sequence coding for said recombinant protein. The process of Claim 5 or 6 wherein the host cell is Escherichia coli, or yeast, or mammalian cells. A diagnostic reagent for bone metabolic diseases, containing the DNA or RNA of Claim 3 or 4. A diagnostic reagent for bone metabolic diseases, containing the protein of Claim 1. A polyclonal or monoclonal antibody against the protein of Claim 1. A diagnostic reagent for bone metabolic diseases, containing the antibody of Claim 10. A therapeutic agent for bone metabolic diseases, containing the protein of Claim 1.

Inventors: AMANN EGON DR, ITO TOSHIMI, OTAWARA-HAMAMOTO YOKO, TAKESHITA SUNAO, AMANN, EGON, DR., ITO, TOSHIMI, OTAWARA-HAMAMOTO, YOKO, TAKESHITA, SUNAO
Applicants: HOECHST MARION ROUSSEL LTD, HOECHST MARION ROUSSEL, LTD.
Application year: 1993
Main classification: C12N15
IPC codes: C12P21, A61K38, A61K36, C12N15, A61K39, A61P43, A61P3, A61K35, G01N33, C12N9, A61K49